In the present study, the integrative analysis of WES, RNA-seq, tumor PD-L1 expression by IHC, tumor CD8+ T cell infiltration by IF, and clinical outcomes on ICI monotherapy from pre-treatment samples of patients with metastatic renal cell carcinoma on two clinical trials (CheckMate 010 and CheckMate 025) allowed the in-depth examination of the immune characteristics of these tumors. This evidence concerns the gene CD8A and neoplasm.